Abstract Library

#3002 Quality of Life, Tumour Heterogeneity and Biomarker Levels in Patients with Progressive Pancreatic or Midgut Neuroendocrine Tumours: Baseline Data from CLARINET FORTE

Introduction: Lanreotide autogel (LAN) 120 mg every (q)28 days (standard regimen) improves progression-free survival vs placebo in patients with advanced, somatostatin receptor-positive (SSTR+) gastroenteropancreatic neuroendocrine tumours (NETs).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Ruszniewski P, Ćwikła J, Lombard-Bohas C, Borbath I, Shah T,

Keywords: Neuroendocrine tumours, lanreotide,

#2916 Pretherapeutic Heterogeneity of Somatostatin Receptor Expression in Neuroendocrine Neoplasia: An Innovative Predictor of Response to Everolimus?

Introduction: In patients with bronchopulmonary or gastroenteropancreatic neuroendocrine neoplasms (NEN) the mTOR inhibitor everolimus may prolong progression-free survival (PFS). However, this is countered by potentially significant toxicity.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Wetz C, Genseke P, Schatka I, Jann H, Rogasch J,

Keywords: Neuroendocrine Neoplasia, Asphericity, Everolimus, Prediction,

#2232 Role of Interval Reduction of Somatostatin Analogs in Patients with Progressive Neuroendocrine Tumors: Our Experience

Introduction: Interval reduction of somatostatin analogs (SSAs) is a possibly strategy for elderly patients with progressive metastatic neuroendocrine tumors (NETs). Patients with diagnosis of NET are >75 years old in the 25% of cases. No randomized studies are available to evaluate efficacy of this treatment schedule.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Puliafito I, Prestifilippo A, Colarossi C, Giuffrida P, Castorina L,

Keywords: somatostatin, analogs, interval, reduction, experience, elderly,

#2212 A Rare Case of Paraneoplastic Hypercalcemia Secondary to a Neuroendocrine Pancreatic Tumour (pNET).

Introduction: Paraneoplastic hypercalcemia (HC) is a well-described affection in literature. It can relay on several mechanisms among with bone osteolysis, Parathormone (PTH) related peptide (rp) production, primary hyperparathyroidism, and Calcitriol (CT) secretion. CT secretion-mediated HC is more frequently observed among lymphomas and has only been once reported in pNET.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Belaïd A, Dhenin A, Jopart P, Seront E, Grandjean M,

Keywords: paraneoplastic hypercalcemia, pancreatic neuroendocrine tumor, calcitriol,

#2195 Audit of a New Nurse-Led Non-Medical Prescribing (NMP) Clinic for Systemic Anti-Cancer Agents (SACTs)

Introduction: The number of people living with cancer in the UK continues to rise with increased demands on specialist cancer care services. NET incidence and prevalence increases alongside this demand. NETs remain a rare cancer with specialist needs. The clinical nurse specialist (CNS) is ideally placed to support these patients. Oncology clinics are increasingly pressured, the need to think of innovative ways of reducing strain whilst maintaining and enhancing the patients experience is important. To address this we set up a nurse-led SACT NMP clinic alongside the oncology clinic to improve patient experience and reduce oncologist clinic review.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Davies P

Authors: Davies P, Quaglia E, McSweeney A, Caplin M, Thirlwell C,

Keywords: Nurse, Non-Medical Prescribing, SACTs, neuroendocrine, chemotherapy, everolimus, sunitinib,